98 related articles for article (PubMed ID: 26695694)
1. Jade-1: its structure, regulation and functions in the renal cancer.
Zhang YC; Du WQ; Zhang RY; Zheng JN; Pei DS
Curr Mol Med; 2016; 16(1):63-9. PubMed ID: 26695694
[TBL] [Abstract][Full Text] [Related]
2. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
[TBL] [Abstract][Full Text] [Related]
3. von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity.
Panchenko MV; Zhou MI; Cohen HT
J Biol Chem; 2004 Dec; 279(53):56032-41. PubMed ID: 15502158
[TBL] [Abstract][Full Text] [Related]
4. Polycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1.
Foy RL; Chitalia VC; Panchenko MV; Zeng L; Lopez D; Lee JW; Rana SV; Boletta A; Qian F; Tsiokas L; Piontek KB; Germino GG; Zhou MI; Cohen HT
Hum Mol Genet; 2012 Dec; 21(26):5456-71. PubMed ID: 23001567
[TBL] [Abstract][Full Text] [Related]
5. Jade-1, a candidate renal tumor suppressor that promotes apoptosis.
Zhou MI; Foy RL; Chitalia VC; Zhao J; Panchenko MV; Wang H; Cohen HT
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):11035-40. PubMed ID: 16046545
[TBL] [Abstract][Full Text] [Related]
6. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL.
Chitalia VC; Foy RL; Bachschmid MM; Zeng L; Panchenko MV; Zhou MI; Bharti A; Seldin DC; Lecker SH; Dominguez I; Cohen HT
Nat Cell Biol; 2008 Oct; 10(10):1208-16. PubMed ID: 18806787
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for renal cancer by the dynamics of pVHL-dependent JADE1 stabilization and β-catenin regulation.
Shafique S; Rashid S
Prog Biophys Mol Biol; 2019 Aug; 145():65-77. PubMed ID: 30528740
[TBL] [Abstract][Full Text] [Related]
8. Beta-catenin gets jaded and von Hippel-Lindau is to blame.
Berndt JD; Moon RT; Major MB
Trends Biochem Sci; 2009 Mar; 34(3):101-4. PubMed ID: 19217300
[TBL] [Abstract][Full Text] [Related]
9. The ciliary protein nephrocystin-4 translocates the canonical Wnt regulator Jade-1 to the nucleus to negatively regulate β-catenin signaling.
Borgal L; Habbig S; Hatzold J; Liebau MC; Dafinger C; Sacarea I; Hammerschmidt M; Benzing T; Schermer B
J Biol Chem; 2012 Jul; 287(30):25370-80. PubMed ID: 22654112
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
11. Jade-1S phosphorylation induced by CK1α contributes to cell cycle progression.
Borgal L; Rinschen MM; Dafinger C; Liebrecht VI; Abken H; Benzing T; Schermer B
Cell Cycle; 2016; 15(8):1034-45. PubMed ID: 26919559
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of von Hippel-Lindau downstream genes: Jade-1 and β-catenin related to renal cell carcinoma.
Lian X; Duan X; Wu X; Li C; Chen S; Wang S; Cai Y; Weng Z
Urology; 2012 Aug; 80(2):485.e7-13. PubMed ID: 22516360
[TBL] [Abstract][Full Text] [Related]
13. Casein kinase 1 α phosphorylates the Wnt regulator Jade-1 and modulates its activity.
Borgal L; Rinschen MM; Dafinger C; Hoff S; Reinert MJ; Lamkemeyer T; Lienkamp SS; Benzing T; Schermer B
J Biol Chem; 2014 Sep; 289(38):26344-26356. PubMed ID: 25100726
[TBL] [Abstract][Full Text] [Related]
14. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
15. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
16. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
17. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
18. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
19. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
Kuehn EW; Walz G; Benzing T
Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
[TBL] [Abstract][Full Text] [Related]
20. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.
Kamada M; Suzuki K; Kato Y; Okuda H; Shuin T
Cancer Res; 2001 May; 61(10):4184-9. PubMed ID: 11358843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
